Jul 2026· Journal of Alzheimer's Disease· Vol 113, pp. 796 - 812· 0 citations· 65 references
Medicine
TL;DR
MRI-derived longitudinal features enhance atrophy prediction, and predicted atrophy rates provide sensitive markers of future cognitive decline support the potential utility of predicted atrophy for cohort enrichment and therapeutic trial design.
Abstract
Background Neuron loss is a hallmark of neurodegenerative diseases and leads to brain atrophy detectable with magnetic resonance imaging (MRI). Accurate prediction of future atrophy is valuable for research in Alzheimer's disease (AD) and related dementias. Objective This study aimed to predict annualized percentage changes in hippocampal, ventricular, and total gray matter (TGM) volumes in individuals ranging from cognitively normal to dementia, and to evaluate whether longitudinal MRI-derived change measures improve prediction performance compared with single-time-point MRI information. Methods Using elastic net regression, we compared baseline models based on single-timepoint MRI information with longitudinal models incorporating prior MRI-derived change measures. Both approaches were evaluated as MRI-only and MRI + risk-factor variants, with risk factors including age, sex, APOE4, and diagnostic status. Results In cross-validated analyses using the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, the longitudinal MRI + risk-factor model performed best, yielding Pearson correlations of 0.62 for hippocampal atrophy, 0.51 for ventricular enlargement, and 0.41 for TGM atrophy. Longitudinal models consistently outperformed single time-point models, and adding risk factors improved predictive performance beyond MRI alone. External validation using the Australian Imaging, Biomarkers and Lifestyle cohort confirmed these findings. Predicted atrophy outperformed present-day regional volumes in identifying individuals progressing from normal cognition to MCI/dementia and from MCI to dementia. Conclusions MRI-derived longitudinal features enhance atrophy prediction, and predicted atrophy rates provide sensitive markers of future cognitive decline. These findings support the potential utility of predicted atrophy for cohort enrichment and therapeutic trial design.
Bomarker-confirmed AD comprised internally reproducible atrophy trajectories with distinct cognitive, vascular, and molecular profiles and may complement fluid biomarkers and conventional volumetry for patient stratification and prognosis.
Chen-Hui Mao, Yu-Yue Qiu, Bo Li et al.· NeuroImage· 0 citations
It is suggested that MRI-derived measures of cortical thickness, tissue volumes, BPV, and BPF provide useful structural biomarkers of AD and emphasize the importance of considering voxel geometry and segmentation methodology when evaluating neuroimaging biomarkers.
Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...
L. Gualco, N. Montobbio, M. Losa et al.· European Radiology Experimen...· 0 citations
MRI-derived brain-PAD predicts progression to dementia in memory clinic patients with SCD or MCI and provided additional predictive value to visual rating scales in patients with SCD and mild cognitive impairment.
S. de Vries, K. Farkas, Hanneke F. M. Rhodius-Meester et al.· Neurology· 0 citations
Alzheimer’s disease (AD) is a progressive neurological disorder and the leading cause of dementia, affecting millions globally. As populations continue to age, AD prevalence is expected to rise significantly, placing substantial burdens on healthcare systems. Early detection of cognitive decline is essential, as interv...
Samaneh Rezaeimanesh, Mohammad Fili, Gui-Ping Hu et al.· IISE Annual Conference &...· 0 citations
Objective Alzheimer’s disease (AD) is characterized by amyloid deposition, brain hypometabolism, gray matter atrophy and cognitive decline, yet their causal interactions are poorly defined. This multimodal PET/MRI study explored regional gray matter volume (GMV) loss and glucose hypometabolism in AD patients, and clari...
Shi-Qi Zhao, Jian-Wen Chen, Pei-Xue Li et al.· Frontiers in Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.